Objectives: Bartonella sp. are intracellular bacteria associated with an increasing number of clinical manifestations but with few published data on in vitro susceptibility testing of antibiotics. Our objective was to evaluate in vitro antibiotic susceptibilities of 20 new Bartonella isolates from animals in Australia.
Introduction
Bartonella species are Gram-negative bacilli that belong to the a2 subgroup of Proteobacteria.
1 Over the last decade, the number of identified Bartonella sp. has increased rapidly and the family Bartonellaceae now contains 22 validated species and 3 subspecies. To date, 11 species have been associated with an increasing spectrum of clinical syndromes in humans including cat scratch disease (Bartonella henselae), Bacillary angiomatosis, Peliosis hepatitis (B. henselae, Bartonella quintana), bacteraemia and/or endocartitis (B. henselae, B. quintana, Bartonella vinsonii subsp. arupensis, Bartonella alsatica and Bartonella rochalimae), Carrions disease (Bartonella bacilliformis), trench fever (B. quintana), retinitis (B. henselae, Bartonella grahamii), myocarditis (Bartonella washoensis) and splenomegaly (B. rochalimae).
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Treatment of human bartonellosis depends on clinical disease, and current recommendations for treatment are based on a few case reports and very limited data from a few clinical studies. 2 Moreover, due to the fastidious nature of these bacteria and the limited number of available isolates worldwide, few data on in vitro susceptibility have been reported. Although successful treatment of Bartonella infections with fluoroquinolones has been reported, there have also been failures and relapses with these drugs. 2 Fluoroquinolone antibiotics exert their antibacterial effects by inhibition of DNA gyrase (topoisomerase II) and topoisomerase IV. Bacterial resistance to quinolones can essentially develop either by point mutations in the quinolone-resistance-determining region (QRDR) of both gyrase (gyrA) and topoisomerase IV ( parC), or by efflux mechanisms.
In the present study, we have determined the MICs of 11 antimicrobial agents by Etest for 20 new Bartonella strains from Australia isolated from the blood of different animals including kangaroos and rodents. Moreover, we have determined the sequences of the QRDR of gyrA gene for these isolates and compared them with the available sequences of Bartonella reference strains in order to explain the molecular basis of the heterogeneity of susceptibility to fluoroquinolone compounds.
Materials and methods

Bartonella strains
Twenty-four strains of Bartonella species were tested including 20 strains of Bartonella sp. isolated from the blood of wild animals in Australia and from four reference strains (Table 1 ). All animal trapping and blood collection was carried out in accordance with 'The Australian Code of Practice for the Care and Use of Animals for Scientific Purposes'.
Drugs
Etest strips for erythromycin, clarithromycin, ceftriaxone, tetracycline, azithromycin, ofloxacin, amoxicillin, imipenem, vancomycin, ciprofloxacin and rifampicin were purchased from AB BIODISK (Solna, Sweden).
Antibiotic susceptibility testing
The bacteria were grown on Columbia 5% sheep blood agar plates and incubated at 378C in a 5% CO 2 -enriched atmosphere. Antibiotic susceptibility testing was carried out with the same agar medium containing an Etest strip and observed daily for growth as previously reported. 3 MICs were read after an incubation of 5 -12 days. Susceptibility testing was performed twice for each strain and antimicrobial agent in order to confirm the results.
Staphylococcus aureus ATCC 29213 and Escherichia coli ATCC 25922 were used as controls.
Extraction of DNA
Total genomic DNA was extracted from Bartonella isolates with a QIAamp Tissue kit (Qiagen, Hilden, Germany), as described by the manufacturer. Samples were handled under sterile conditions to avoid the risk of cross-contamination.
DNA amplification and sequencing of gyrA gene
Bartonella strains from Australia were screened for the presence of mutations in the QRDR of gyrA gene by PCR amplification and DNA sequencing using specific oligonucleotide primers BagyrAR and BagyrAF, published by Biswas et al. 4 The obtained nucleotide sequences of candidate genes were compared using the CLUSTAL W program (http://www.ebi.ac.uk/clustalw/) to look at possible 
Discussion
In this study, 20 Bartonella sp. isolates from animals from Australia were tested for their antibiotic susceptibilities to 11 antimicrobial agents using the Etest assay. Evaluation of susceptibility to antibiotics in Bartonella genus has been previously assessed either in the presence of eukaryotic cells or in axenic media especially by the agar dilution technique. 2 Recently, we and others have reported the reliability, sensitivity and usefulness of the Etest assay for determination of MICs for the Bartonella genus. 4, 5 This assay was used in the present study with consistent and similar results when compared with other Bartonella species. 2 The Bartonella isolates from Australia were susceptible to aminoglycosides, macrolides, doxycycline and rifampicin, and were resistant to vancomycin.
Imipenem was effective against all the strains except one (Nh4) that had an MIC of 3 mg/L. In this strain, we suspected the presence of a metallo-b-lactamase (MBL) gene either chromosomally mediated or encoded by transferable genes. MBL genes has been found in many Gram-negative bacteria including B. bacilliformis (http://www.genome.jp/kegg/).
Interestingly, we found heterogeneity of susceptibility to fluoroquinolones with ciprofloxacin to be more effective than with ofloxacin. Ofloxacin MICs were 10-fold higher compared with ciprofloxacin. Looking at previous results obtained for other Bartonella strains, we found that ciprofloxacin was also more effective when compared with pefloxacin. 2, 6, 7 We found that this heterogeneity of susceptibility to fluoroquinolones was linked to a natural mutation at position 83 of the QRDR of the DNA gyrase. In vitro studies with E. coli suggest that the first step in selection for decreased susceptibility to fluoroquinolones was an alteration of Ser-83. 8 Studies suggest that not all mutations in gyrA confer the same level of resistance to all quinolones, and mutations at codons Ser-83 and Asp-87 appear most frequently and confer higher levels of quinolone resistance than mutations at other codons within the QRDR. Moreover, strains with a single mutation at Ser-83 were significantly more resistant to fluoroquinolones than those with a single mutation at Asp-87 because mutations at this active site may alter the binding of quinolones to the site and lead to reduced susceptibility or resistance to quinolones. According to Heisig and Tschorny, 8 a mutation at codon Ser-83!Ala in E. coli leads to MICs of ciprofloxacin that are lower than MICs of ofloxacin, whereas E. coli strains with double mutations in Ser-83!Ala and Asp-87!Gly present a high level of resistance for all compounds. This was also observed for a ciprofloxacin-resistant B. bacilliformis strain obtained in vitro with a double mutation. 4 Surprisingly, the same mutation was also found in other Bartonella strains including B. henselae strain Houston, B. henselae strain Marseille, B. bacilliformis and B. quintana strain Oklahoma.
Minnick et al. 9 and our team have recently reported gyrA mutations in ciprofloxacin-resistant B. bacilliformis strains obtained in vitro at position Asp-87!Asn (E. coli numbering) of the QRDR of the DNA gyrase. 4, 9 In these two reports, the Ser-83!Ala mutation was also present in the QRDR of the DNA gyrase but it was not mentioned (J.-M. R., unpublished data). We believe that the heterogeneity of susceptibility to fluoroquinolones in the Bartonella genus is due to this natural mutation at position 83 but additional factors such as decreased intracellular drug accumulation by drug efflux or plasmidquinolone resistance gene (qnr) may also occur. This natural mutation at position 83 may also explain heterogeneity of susceptibility to fluoroquinolones reported for other intracellular bacteria including Tropheryma whipplei and bacteria of the genus Brucella.
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Our findings have clinical significance and could explain relapses observed using ciprofloxacin for treatment of Bartonella infections especially for the treatment of Oroya fever or ocular infections. 2 Since a high level of resistance by a second mutation in the QRDR could be obtained easily in vitro, 4,9 we believe that fluoroquinolones should not be used for the treatment of any Bartonella-related disease.
